130.12
5.23 (4.19%)
| Penutupan Terdahulu | 124.89 |
| Buka | 125.27 |
| Jumlah Dagangan | 2,197,118 |
| Purata Dagangan (3B) | 2,197,961 |
| Modal Pasaran | 17,253,902,336 |
| Harga / Jualan (P/S) | 14.79 |
| Harga / Buku (P/B) | 55.67 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 29 Jul 2026 |
| Margin Keuntungan | -53.82% |
| Margin Operasi (TTM) | -54.33% |
| EPS Cair (TTM) | -3.39 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 20.80% |
| Nisbah Semasa (MRQ) | 4.11 |
| Aliran Tunai Operasi (OCF TTM) | -272.26 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -67.71 M |
| Pulangan Atas Aset (ROA TTM) | -18.64% |
| Pulangan Atas Ekuiti (ROE TTM) | -4,584.47% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Diagnostics & Research (US) | Bercampur | Menaik |
| Diagnostics & Research (Global) | Bercampur | Menaik | |
| Stok | Guardant Health, Inc. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 2.0 |
| Aktiviti Orang Dalam | -3.5 |
| Volatiliti Harga | -1.5 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 4.0 |
| Purata | 0.20 |
|
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched a lab-developed test version of Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals. |
|
| Sektor | Healthcare |
| Industri | Diagnostics & Research |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 4.53% |
| % Dimiliki oleh Institusi | 97.57% |
Tiada data dalam julat masa ini.
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| HIDALGO MEDINA MANUEL | - | 133.22 | -1,000 | -133,220 |
| JOYCE MEGHAN V. | - | 127.03 | -10,000 | -1,270,300 |
| KROGNES STEVE E. | - | 133.06 | -9,294 | -1,236,660 |
| SAIA JOHN G. | - | 127.51 | -10,000 | -1,275,100 |
| Jumlah Keseluruhan Kuantiti Bersih | -30,294 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -3,915,280 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 130.21 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| KROGNES STEVE E. | Pengarah | 04 Jun 2026 | Jual (-) | 9,294 | 133.06 | 1,236,660 |
| JOYCE MEGHAN V. | Pengarah | 03 Jun 2026 | Jual (-) | 10,000 | 127.03 | 1,270,300 |
| JOYCE MEGHAN V. | Pengarah | 03 Jun 2026 | Pelaksanaan pilihan | 10,000 | - | - |
| KROGNES STEVE E. | Pengarah | 31 May 2026 | Pelaksanaan pilihan | 154 | - | - |
| HIDALGO MEDINA MANUEL | Pengarah | 28 May 2026 | Jual (-) | 1,000 | 133.22 | 133,220 |
| SAIA JOHN G. | Pegawai | 27 May 2026 | Jual (-) | 10,000 | 127.51 | 1,275,100 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |